Technical Analysis for AGRX - Agile Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bullish | Bullish Swing Setup | -0.70% | |
| Calm After Storm | Range Contraction | -0.70% | |
| Narrow Range Bar | Range Contraction | -0.70% | |
| Upper Bollinger Band Walk | Strength | -0.70% | |
| Inside Day | Range Contraction | -0.70% | |
| Wide Bands | Range Expansion | -0.70% | |
| Above Upper BB | Strength | -0.70% | |
| Crossed Above 20 DMA | Bullish | -1.39% | |
| Crossed Above 50 DMA | Bullish | -1.39% | |
| MACD Bullish Centerline Cross | Bullish | -1.39% |
| Alert | Time |
|---|---|
| Down 1% | about 7 hours ago |
| Down 5% | 3 days ago |
| Down 3% | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Down 2 % | 3 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Alcohol Clinical Development Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Alcohol Clinical Development Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.0401 |
| 52 Week Low | 0.2 |
| Average Volume | 646,137 |
| 200-Day Moving Average | 1.48 |
| 50-Day Moving Average | 0.45 |
| 20-Day Moving Average | 0.48 |
| 10-Day Moving Average | 0.57 |
| Average True Range | 0.11 |
| RSI (14) | 87.64 |
| ADX | 35.18 |
| +DI | 75.63 |
| -DI | 4.71 |
| Chandelier Exit (Long, 3 ATRs) | 1.13 |
| Chandelier Exit (Short, 3 ATRs) | 0.66 |
| Upper Bollinger Bands | 1.12 |
| Lower Bollinger Band | -0.16 |
| Percent B (%b) | 1.25 |
| BandWidth | 269.10 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.1141 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.48 | ||||
| Resistance 3 (R3) | 1.47 | 1.46 | 1.47 | ||
| Resistance 2 (R2) | 1.46 | 1.45 | 1.46 | 1.46 | |
| Resistance 1 (R1) | 1.44 | 1.44 | 1.44 | 1.45 | 1.46 |
| Pivot Point | 1.43 | 1.43 | 1.42 | 1.43 | 1.43 |
| Support 1 (S1) | 1.41 | 1.42 | 1.41 | 1.42 | 1.40 |
| Support 2 (S2) | 1.40 | 1.41 | 1.40 | 1.40 | |
| Support 3 (S3) | 1.38 | 1.40 | 1.39 | ||
| Support 4 (S4) | 1.39 |
